Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer[1][2].
Molecular Weight:
(144.87 kDa)
Purity:
97.80
CAS Number:
[915404-94-3]
Target:
CCR
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
